US6048859A
(en)
|
1992-06-29 |
2000-04-11 |
Merck & Co., Inc. |
Morpholine and thiomorpholine tachykinin receptor antagonists
|
US5637699A
(en)
*
|
1992-06-29 |
1997-06-10 |
Merck & Co., Inc. |
Process for preparing morpholine tachykinin receptor antagonists
|
US5719147A
(en)
*
|
1992-06-29 |
1998-02-17 |
Merck & Co., Inc. |
Morpholine and thiomorpholine tachykinin receptor antagonists
|
IL111960A
(en)
*
|
1993-12-17 |
1999-12-22 |
Merck & Co Inc |
Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
|
CZ288176B6
(en)
*
|
1993-12-29 |
2001-05-16 |
Merck Sharp & Dohme |
Substituted morpholine derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical preparations in which they are comprised
|
US5610165A
(en)
*
|
1994-02-17 |
1997-03-11 |
Merck & Co., Inc. |
N-acylpiperidine tachykinin antagonists
|
IL112778A0
(en)
*
|
1994-03-04 |
1995-05-26 |
Merck & Co Inc |
Substituted heterocycles, their preparation and pharmaceutical compositions containing them
|
WO1995030674A1
(en)
*
|
1994-05-05 |
1995-11-16 |
Merck Sharp & Dohme Limited |
Morpholine derivatives and their use as antagonists of tachikinins
|
PT777659E
(pt)
*
|
1994-08-15 |
2001-09-28 |
Merck Sharp & Dohme |
Derivados de morfolina e sua utilizacao como agentes terapeuticos
|
GB9417956D0
(en)
*
|
1994-09-02 |
1994-10-26 |
Merck Sharp & Dohme |
Therapeutic agents
|
US5457107A
(en)
*
|
1994-09-16 |
1995-10-10 |
Merck & Co., Inc. |
Polymorphic form of a tachykinin receptor antagonist
|
FR2728165A1
(fr)
*
|
1994-12-19 |
1996-06-21 |
Oreal |
Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
|
GB9426102D0
(en)
*
|
1994-12-23 |
1995-02-22 |
Merck Sharp & Dohme |
Pharmacuetical compositions
|
GB9426103D0
(en)
*
|
1994-12-23 |
1995-02-22 |
Merck Sharp & Dohme |
Therapeutic agents
|
FR2729954B1
(fr)
*
|
1995-01-30 |
1997-08-01 |
Sanofi Sa |
Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
|
DE19504627A1
(de)
*
|
1995-02-13 |
1996-08-14 |
Bayer Ag |
Verfahren und neue Zwischenprodukte zur Herstellung von Triazolinonen
|
GB9505492D0
(en)
*
|
1995-03-18 |
1995-05-03 |
Merck Sharp & Dohme |
Therapeutic agents
|
GB9505491D0
(en)
*
|
1995-03-18 |
1995-05-03 |
Merck Sharp & Dohme |
Therapeutic agents
|
GB9511031D0
(en)
*
|
1995-06-01 |
1995-07-26 |
Merck Sharp & Dohme |
Chemical process
|
GB9513117D0
(en)
*
|
1995-06-28 |
1995-08-30 |
Merck Sharp & Dohme |
Therapeutic agents
|
GB9513118D0
(en)
*
|
1995-06-28 |
1995-08-30 |
Merck Sharp & Dohme |
Therapeutic agents
|
GB9513121D0
(en)
*
|
1995-06-28 |
1995-08-30 |
Merck Sharp & Dohme |
Therapeutic agents
|
GB9523244D0
(en)
*
|
1995-11-14 |
1996-01-17 |
Merck Sharp & Dohme |
Therapeutic agents
|
PT785198E
(pt)
*
|
1996-01-19 |
2000-11-30 |
Lonza Ag |
Processo para a producao de 3-quinuclidinol opticamente activo.
|
GB9603136D0
(en)
*
|
1996-02-15 |
1996-04-17 |
Merck Sharp & Dohme |
Therapeutic agents
|
GB9603137D0
(en)
*
|
1996-02-15 |
1996-04-17 |
Merck Sharp & Dohme |
Therapeutic agents
|
UA56185C2
(uk)
|
1996-09-30 |
2003-05-15 |
Пфайзер Інк. |
Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
|
US6423708B1
(en)
|
1996-09-30 |
2002-07-23 |
Pfizer Inc |
Aralkyl and aralkylidene heterocyclic lactams and imides
|
US6117855A
(en)
|
1996-10-07 |
2000-09-12 |
Merck Sharp & Dohme Ltd. |
Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
|
JP2001502311A
(ja)
*
|
1996-10-07 |
2001-02-20 |
メルク シヤープ エンド ドーム リミテツド |
抗鬱及び/又は抗不安薬としてのcns浸透性nk―1受容体拮抗薬
|
US5750549A
(en)
*
|
1996-10-15 |
1998-05-12 |
Merck & Co., Inc. |
Cycloalkyl tachykinin receptor antagonists
|
WO1998024445A1
(en)
*
|
1996-12-02 |
1998-06-11 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating schizophrenic disorders
|
DE69731658T2
(de)
*
|
1996-12-02 |
2005-12-01 |
Merck Sharp & Dohme Ltd., Hoddesdon |
Die verwendung von nk-1 rezeptor antagonisten für die behandlung von bewegungsstörungen
|
US6613765B1
(en)
|
1996-12-02 |
2003-09-02 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating major depressive disorders
|
AU733855B2
(en)
*
|
1996-12-02 |
2001-05-31 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating major depressive disorders
|
US6100256A
(en)
*
|
1996-12-02 |
2000-08-08 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptors antagonists for treating schizophrenic disorders
|
EP0942733B1
(en)
*
|
1996-12-02 |
2005-04-27 |
MERCK SHARP & DOHME LTD. |
Use of nk-1 receptor antagonists for treating cognitive disorders
|
JP2001504851A
(ja)
*
|
1996-12-02 |
2001-04-10 |
メルク シヤープ エンド ドーム リミテツド |
性的機能不全の治療のためのnk−1受容体拮抗薬の使用
|
US6114315A
(en)
*
|
1996-12-02 |
2000-09-05 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
|
WO1998024443A1
(en)
*
|
1996-12-02 |
1998-06-11 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating bipolar disorders
|
US5977104A
(en)
*
|
1996-12-02 |
1999-11-02 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptor antagonists for treating bipolar disorders
|
ES2231901T3
(es)
*
|
1996-12-02 |
2005-05-16 |
MERCK SHARP & DOHME LTD. |
Uso de antagonistas del receptor de nk-1 para tratar transtornos por el uso de sustancias.
|
EP0941093B1
(en)
*
|
1996-12-02 |
2005-02-09 |
MERCK SHARP & DOHME LTD. |
Use of nk-1 receptor antagonists for treating major depressive disorders with anxiety
|
EP0942734A1
(en)
*
|
1996-12-02 |
1999-09-22 |
MERCK SHARP & DOHME LTD. |
Use of nk-1 receptor antagonists for treating severe anxiety disorders
|
DE69730515T2
(de)
*
|
1996-12-02 |
2005-09-01 |
Merck Sharp & Dohme Ltd., Hoddesdon |
Die verwendung von nk-1 rezeptor antagonisten für die behandlungen von stress störungen
|
RU2184538C2
(ru)
*
|
1997-01-09 |
2002-07-10 |
Бифодан А/С |
Применение дихлорбензилового спирта для получения лекарственного средства для местного лечения воспаления и лекарственное средство, содержащее дихлорбензиловый спирт
|
CA2287487A1
(en)
*
|
1997-04-24 |
1998-10-29 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating eating disorders
|
ZA985765B
(en)
*
|
1997-07-02 |
1999-08-04 |
Merck & Co Inc |
Polymorphic form of a tachykinin receptor antagonist.
|
CA2298777A1
(en)
*
|
1997-08-04 |
1999-02-18 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating mania
|
GB9716457D0
(en)
*
|
1997-08-04 |
1997-10-08 |
Merck Sharp & Dohme |
Therapeutic agents
|
GB9716463D0
(en)
*
|
1997-08-04 |
1997-10-08 |
Merck Sharp & Dohme |
Therapeutic agents
|
AU737019B2
(en)
*
|
1997-08-04 |
2001-08-09 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating aggressive behaviour disorders
|
US6087348A
(en)
*
|
1997-12-01 |
2000-07-11 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptor antagonists for treating stress disorders
|
US6271230B1
(en)
|
1997-12-01 |
2001-08-07 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating cognitive disorders
|
US6156749A
(en)
*
|
1997-12-01 |
2000-12-05 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating movement disorders
|
GB9810920D0
(en)
*
|
1998-05-21 |
1998-07-22 |
Merck Sharp & Dohme |
Therapeutic use
|
GB9816897D0
(en)
*
|
1998-08-04 |
1998-09-30 |
Merck Sharp & Dohme |
Therapeutic use
|
GB9819888D0
(en)
*
|
1998-09-11 |
1998-11-04 |
Merck Sharp & Dohme |
Chemical synthesis
|
US6218390B1
(en)
*
|
1998-12-17 |
2001-04-17 |
Synaptic Pharmaceutical Corporation |
Morpholinone and morpholine derivatives and uses thereof
|
ES2304984T3
(es)
|
1999-11-03 |
2008-11-01 |
Amr Technology, Inc. |
Tetra-hidroisoquinolinas de sustitucion arilica y heteroarilica y su utilizacion para bloquear la recaptacion de norepinefrina, dopamina y serotonina.
|
US7163949B1
(en)
|
1999-11-03 |
2007-01-16 |
Amr Technology, Inc. |
4-phenyl substituted tetrahydroisoquinolines and use thereof
|
PT1103545E
(pt)
*
|
1999-11-29 |
2004-03-31 |
Hoffmann La Roche |
2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-totil-piridin-3-il)-isobutiramida
|
RU2301808C2
(ru)
|
2000-07-11 |
2007-06-27 |
Эймр Текнолоджи, Инк. |
4-фенилзамещенные тетрагидроизохинолины, фармацевтическая композиция и способ лечения на их основе
|
GB0022988D0
(en)
*
|
2000-09-19 |
2000-11-01 |
Merck Sharp & Dohme |
Therapeutic agents
|
US6638981B2
(en)
|
2001-08-17 |
2003-10-28 |
Epicept Corporation |
Topical compositions and methods for treating pain
|
AU2003282665A1
(en)
*
|
2002-10-11 |
2004-05-04 |
Cytokinetics, Inc. |
Compounds, compositions, and methods
|
WO2005090300A1
(en)
|
2004-03-17 |
2005-09-29 |
Pfizer Products Inc. |
Novel benzyl(idene)-lactam derivatives
|
GEP20094640B
(en)
|
2004-07-15 |
2009-03-10 |
Bristol Myers Squibb Co |
Aryl-and heteroaryl-substituted tetrahydro isoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
|
ATE550019T1
(de)
|
2005-05-17 |
2012-04-15 |
Merck Sharp & Dohme |
Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
|
BRPI0613403A2
(pt)
|
2005-07-15 |
2009-02-10 |
Amr Technology Inc |
tetrahidrobenzodiazepinas aril- e heteroarila-substituÍdas e uso das mesmas para bloquear a recaptaÇço de norepinefrina, dopamina e serotonina
|
CA2624030A1
(en)
|
2005-09-29 |
2007-04-12 |
Tianying Jian |
Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
EP2083831B1
(en)
|
2006-09-22 |
2013-12-25 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
JP4611444B2
(ja)
|
2007-01-10 |
2011-01-12 |
イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー |
ポリ(adp−リボース)ポリメラーゼ(parp)阻害剤としてのアミド置換インダゾール
|
EP2117538A1
(en)
|
2007-01-24 |
2009-11-18 |
Glaxo Group Limited |
Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
|
EP2145884B1
(en)
|
2007-04-02 |
2014-08-06 |
Msd K.K. |
Indoledione derivative
|
WO2008130616A2
(en)
*
|
2007-04-19 |
2008-10-30 |
Schering Corporation |
Diaryl morpholines as cb1 modulators
|
US8389553B2
(en)
|
2007-06-27 |
2013-03-05 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
EP2254420A4
(en)
|
2008-02-20 |
2012-02-15 |
Targia Pharmaceuticals |
CNS PHARMACEUTICALS AND METHOD FOR THEIR USE
|
JP2011515343A
(ja)
|
2008-03-03 |
2011-05-19 |
タイガー ファーマテック |
チロシンキナーゼ阻害薬
|
WO2009124756A1
(en)
*
|
2008-04-08 |
2009-10-15 |
European Molecular Biology Laboratory (Embl) |
Use of aprepitant and derivatives thereof for the treatment of cancer
|
US9156812B2
(en)
|
2008-06-04 |
2015-10-13 |
Bristol-Myers Squibb Company |
Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
|
AR071997A1
(es)
|
2008-06-04 |
2010-07-28 |
Bristol Myers Squibb Co |
Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
|
US8691825B2
(en)
|
2009-04-01 |
2014-04-08 |
Merck Sharp & Dohme Corp. |
Inhibitors of AKT activity
|
EP2429295B1
(en)
|
2009-05-12 |
2013-12-25 |
Albany Molecular Research, Inc. |
Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
|
KR101830447B1
(ko)
|
2009-05-12 |
2018-02-20 |
알바니 몰레큘라 리써치, 인크. |
7-([1,2,4]트리아졸로[1,5-α]피리딘-6-일)-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로이소퀴놀린 및 이의 용도
|
JP5739415B2
(ja)
|
2009-05-12 |
2015-06-24 |
ブリストル−マイヤーズ スクウィブ カンパニー |
(S)−7−([1,2,4]トリアゾロ[1,5−a]ピリジン−6−イル)−4−(3,4−ジクロロフェニル)−1,2,3,4−テトラヒドロイソキノリンの結晶形態およびその使用
|
CN102638981B
(zh)
|
2009-10-14 |
2015-07-22 |
默沙东公司 |
提高p53活性的取代的哌啶和其用途
|
US8999957B2
(en)
|
2010-06-24 |
2015-04-07 |
Merck Sharp & Dohme Corp. |
Heterocyclic compounds as ERK inhibitors
|
CA2805265A1
(en)
|
2010-08-02 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
|
EP2606134B1
(en)
|
2010-08-17 |
2019-04-10 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
EP2608669B1
(en)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
WO2012030685A2
(en)
|
2010-09-01 |
2012-03-08 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
EP2632472B1
(en)
|
2010-10-29 |
2017-12-13 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
|
EP2654748B1
(en)
|
2010-12-21 |
2016-07-27 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
JP2014514321A
(ja)
|
2011-04-21 |
2014-06-19 |
メルク・シャープ・アンド・ドーム・コーポレーション |
インスリン様増殖因子1受容体阻害剤
|
US9023865B2
(en)
|
2011-10-27 |
2015-05-05 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
EP3453762B1
(en)
|
2012-05-02 |
2021-04-21 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
US9233979B2
(en)
|
2012-09-28 |
2016-01-12 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
RU2660349C2
(ru)
|
2012-11-28 |
2018-07-05 |
Мерк Шарп И Доум Корп. |
Композиции и способы для лечения злокачественной опухоли
|
BR112015013611A2
(pt)
|
2012-12-20 |
2017-11-14 |
Merck Sharp & Dohme |
composto, e, composição farmacêutica
|
WO2014120748A1
(en)
|
2013-01-30 |
2014-08-07 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
EP3706742B1
(en)
|
2017-11-08 |
2023-03-15 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
WO2020033282A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
WO2020033284A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
CA3173697A1
(en)
|
2020-04-03 |
2021-10-07 |
Mike TROWER |
An nk-1 receptor antagonist for treating a disease selecting from sepsis, septic shock, acute respiratory distress syndrome (ards) or multiple organ dysfunction syndrome (mods)
|
EP4157270A1
(en)
|
2020-06-02 |
2023-04-05 |
NeRRe Therapeutics Limited |
Neurokinin (nk)-1 receptor antagonists for use in the treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs
|